157. スタージ・ウェーバー症候群 Sturge-Weber syndrome Clinical trials / Disease details
臨床試験数 : 10 / 薬物数 : 13 - (DrugBank : 4) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04447846 (ClinicalTrials.gov) | October 14, 2019 | 10/10/2019 | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II Trial | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | Jazz Pharmaceuticals;Faneca 66 Foundation | Completed | 3 Years | 50 Years | All | 10 | Phase 2 | United States |
2 | NCT02332655 (ClinicalTrials.gov) | December 2014 | 5/1/2015 | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | GW Pharmaceuticals Ltd.;Faneca 66 Foundation | Active, not recruiting | 1 Month | 45 Years | All | 5 | Phase 1/Phase 2 | United States |